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DISCUSSION
Dr Joseph Mills (Tucson, Ariz). The present study has ex-
panded the application of surveillance to postoperative duplex
evaluation of primarily prosthetic femorofemoral bypass grafts.
Before asking questions of the authors, I would note that the
rationale underlying duplex surveillance of infrainguinal vein grafts
and that behind femorofemoral bypass grafts may be different, and
the two situations may not be comparable. The major premises
underlying duplex surveillance of infrainguinal vein grafts include
the following: (1) vein graft failure most often results from the
development of intrinsic graft stenosis, (2) high-grade vein graft
stenosis will lead to graft thrombosis if not revised, (3) vein graft
stenosis is often clinically silent and not reliably detectable before
graft occlusion by history, physical exam, and simple noninvasive
measurements, (4) vein graft stenoses and low flow states can be
accurately identified, graded, and monitored for progression by
duplex surveillance, (5) prophylactic revision of patent, but failing,
vein grafts yields superior results to those obtained after thrombec-
tomy or thrombolysis and revision of occluded vein grafts, and
(6) vein graft patency and limb salvage rates are significantly
improved by a postoperative duplex surveillance protocol.
Although most vascular surgeons accept these premises for
infrainguinal vein graft surveillance, these basic assumptions may
not apply at all to a prosthetic femorofemoral bypass graft. Femo-
rofemoral grafts can usually be readily resurrected either by revi-
sion and thrombectomy or by lysis and inflow angioplasty. In
addition, the consequences of femorofemoral bypass graft failure
do not appear to be as severe as for infrainguinal vein grafts. These
skeptical thoughts lead to the following questions:
Do you have data on howmany patients with duplex-detected
lesions postfemorofemoral bypass graft had either recurrent symp-
toms or reduced ankle-brachial index measurements and therefore
would have been discovered without duplex surveillance? How do
you assess the inflow prior to performing a femorofemoral bypass
graft?
In the manuscript, the authors note that five of the 11 femo-
rofemoral graft thromboses occurred in the first 6 months after
their performance. This would be quite early for recurrent disease
or progressive disease to have developed after inflow iliac angio-
plasty. Could some of these early graft events be related to inade-
quate inflow assessment or inadequate iliac angioplasty?
Did any patient with a femorofemoral bypass graft thrombosis
lose their leg? From reading the manuscript, it sounds as though
the two patients who required amputation had patent femoro-
femoral bypass grafts and presumably went on to amputation due
to uncorrectable or uncorrected outflow disease. Femorofemoral
graft thrombosis may not be nearly as morbid as infrainguinal vein
graft failure, and therefore, surveillancemay not be cost-effective in
the former circumstance.
Finally, we clearly need better velocity criteria and data on
progression of disease for iliac lesions, especially those proximal to
a femorofemoral bypass graft. The routine use of a peak systolic
velocity of 300 cm/s seems too simplistic and insufficiently spe-
cific. I would also note that midgraft peak systolic velocity is not
likely to be very helpful, since it may be greatly affected by whether
the graft is an 8-mm graft or a 6-mm graft. One should note there
are randomized, prospective trials demonstrating that 8-mm fem-
oropopliteal prosthetic grafts have greater long-term patency than
6-mm grafts, even though the midgraft velocities would be lower
due to the diameter of the conduit.
Dr. Stone.Okay, let me try to answer those questions. If you
looked at the patients we had who developed either a drop in ABI
of 0.2 or recurrent symptoms, that number is around a quarter, so
not all of our patients would have been picked up just based on
history and just basic physical exam in the office. Most of these
patients were asymptomatic at the time of detection of abnormal-
ities.
With regard to early thrombosis, again our patients had duplex
examinations prior to their femorofemoral bypass and it is curious
why we had early thrombosis in several of those patients. Again, if
you look at our results, most of the patients with early failures had
abnormal velocities and at least reviewing these charts myself, what
seemed to happen is you would have a patient come in and they
would have the left side occluded and the right side with a high
velocity. That side would be treated, and a femorofemoral bypass
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would be performed, and then several of those patients when they
came back, they still had high velocities, over 300. We followed
those and then they came back thrombosed. So is it progression of
disease? In that subset, the answer is no. It would probably be
inadequate treatment of the inflow artery.
The benefit that we see as well as the morbidity aspects of a
failed graft—if you look at how we treated these patients—the
benefits were detecting and treating stenosis. Nearly all of our
patients were treated by endovascular means. These were outpa-
tient procedures. The patients came in, and with most of them
being inflow, these were treated endovascularly and there was low
morbidity with that. I think that is one of the major benefits to
detecting the stenosis ahead of time and treating them. The two
patients who did have amputations were secondary to outflow
disease and these patients had concomitant outflow bypasses with
progression of disease and subsequently required amputation, not
secondary to a failed fem-fem but secondary to progression of
outflow disease.
All the grafts—I’m not going to say all, there were two or
maybe three 6-mm grafts—so for the most part, our grafts were 8
mm throughout our study period except for the deep vein by-
passes. We do not know exactly what the ideal velocity criteria
should be, but at least looking at our experience here, 300 cm/s
appears to be a good number in that we can keep secondary
patency and primary assisted at about 90% at 5 years, which most
people have not been able to do. If you look at most papers in the
literature on femorofemoral bypass, they just have primary patency
and secondary patency, and they are not much different. So, most
of the time when these fail, and you can even see in our group with
11 patients who had a failed fem-fem bypass, the majority of them
went on to a different procedure, either a redo aortobifem or some
other type of procedure, so once they thrombosed the salvage rate
was low.
Dr Ali AbuRahma (Charleston, WV). If you notice, the
significant bulk of your patients have an inflow corrected by iliac
stenting, and all of us here in this room know with this stenting the
velocity criteria does not apply, similar to what we do with a native
artery. Do you think you need to modify the velocity criteria for
these people because of the presence of a stent? And secondly, have
you looked at any kind of cost benefit ratio in your protocol?
Dr. Stone. First question, if you actually look in the paper in
the results section, actually there was not a statistical significance in
our abstract and then it appeared there was, but actually upon
reviewing, the risk of having a revision was not increased with
someone with a previous iliac stent, so that is different than what is
in the abstract. Have we changed our velocity criteria? Not to my
understanding. We haven’t made any changes based on previous
stenting.
Cost analysis. There is, of course, cost with all duplex surveil-
lance follow-up, but if you can prevent thrombosis, it would not
take but several thromboses and the cost of repeat bypass, and also
that expanded hospitalization, to pay off the duplex surveillance
cost.
Dr Eric Endean (Lexington, KY). The majority of your
failures were due to an inflow stenosis, but you had four anasto-
motic stenoses. Do you have any information about the duplex
findings at the anastomosis as opposed to midgraft velocities or the
inflow velocities?
Dr. Stone. On those four anastomotic problems, they also
had elevated velocities and probably what was not clear in the
presentation is that these areas were treated based on a threshold of
over 300 cm/s, so if we found an anastomosis that had a velocity
over 300 cm/s, of which in this series two of them were outflow,
they underwent balloon angioplasty and that accounted for some
of the primary assisted patency. Two of the patients on the inflow
anastomosis who had problems underwent patch angioplasty, so
they did have abnormalities at that area that were detected by
duplex. The midgraft velocities, as we have seen, are probably
not a real helpful number, but it gives you some type of ballpark.
If they dropped below 60, half of themwent on to failure and if you
looked more carefully at the six people—we had six people over
300 that we have not treated and that’s because they have not had
symptoms—they have not had drop in their ABI, but their midg-
raft velocity stayed above 60 cm/s, and we have been following
them for some time. I don’t have a real good answer on why they
have not failed yet and if they are going to fail. I think we have seen
one of those patients in the meantime who has required revision of
the six that we followed with high velocities.
Dr Stephen Lalka (Charlotte, NC). In your lab, what do you
do for the anastomosis, because obviously, between patients and
within a patient midgraft velocity is reproducible, iliac velocity is
reproducible, but patients may have fem-fems coming off aortob-
ifem limbs. They may have a fem-pop coming off of the femoral
anastomosis, so once you finish that you are going to have a lot of
turbulence, so the initial velocity, say at 1 month when you get
their first velocity, may be elevated just because of the turbulence
because of their particular anatomy in that patient. Do you have
that as their baseline and then follow from that, because that is
independent of their iliac and their midgraft velocity, but yet we see
failures because of intimal hyperplasia at the anastomotic hood
in these types of patients, and then, how do you follow that in
your lab?
Dr. Stone. That’s a good question. I don’t have a specific
answer for that, how our technicians actually do that in the lab, but
on reviewing the studies, we specifically looked at the anastomosis
to see if there was elevated velocity at that area, and I did not
specifically look at the changes that occurred in the velocities from
their first scan to their further followup.
DrMartin Back (Tampa, Fla). I am going to help Patrick out
with one of these issues. Iliac duplex scanning is a little bit difficult
in some of these people with regards to the velocities and sorting
out whether they have focal potentially endovascularly amenable
disease for treatment or more diffuse disease, so some of these
patients that have these velocities over 300 can be more of a diffuse
disease in the external iliac artery ,typically just above the inguinal
ligament, that may not necessarily be amenable to treatment,
because when you go angiogram these people, they have a fairly
large lumen or a lumen that looks patent all the way up through,
but they have clearly got a lot of disease on the posterior wall and
do not have a focal stenosis that can be demonstrated angiographi-
cally.
JOURNAL OF VASCULAR SURGERY
September 2006502 Stone et al
